Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7299650 | 0.89 | NPY5R (0.52) | BDKRB1NPY5RMMP2MMP9MMP8 | |
| SCHEMBL7297288 | 0.89 | NPY5R (0.52) | BDKRB1NPY5RMMP2MMP9MMP8 | |
| SCHEMBL8388668 | 0.82 | SLC1A3 (0.60) | MMP2MMP9MMP8ALDH1A1SLC1A3 | |
| SCHEMBL8388664 | 0.82 | SLC1A3 (0.60) | MMP2MMP9MMP8ALDH1A1SLC1A3 | |
| SCHEMBL7300504 | 0.79 | MMP7 (0.64) | MMP2MMP9MMP8MMP12MMP14 | |
| SCHEMBL8716908 | 0.77 | F2 (0.54) | NPY5RALDH1A1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7297126 | 0.77 | NPY5R (0.49) | BDKRB1NPY5RALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL6951280 | 0.76 | F2 (0.54) | NPY5RMMP2MMP9ALDH1A1SLC1A3 | |
| SCHEMBL5189194 | 0.76 | MMP2 (0.71) | NPY5RMMP2MMP9ALDH1A1SLC1A3 | |
| SCHEMBL7290941 | 0.76 | MMP2 (0.71) | NPY5RMMP2MMP9ALDH1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| CN-119613412-A | Method for synthesizing ruxotinib intermediate through asymmetric hydrogenation | 深圳格林凯特医药技术有限公司 | 2025-03-14 | — | — | CN | claimed |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-05-09 | — | — | US | claimed |
| CN-116082455-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2023-05-09 | — | — | CN | claimed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | claimed |
| EP-4090670-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| CN-115298196-A | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-04 | — | — | CN | claimed |
| CN-115279782-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-01 | — | — | CN | claimed |
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| CN-110903189-B | Synthesis method of chiral 2-aryl propionate | 大连大学 | 2022-06-21 | — | — | CN | claimed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114341161-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-02-10 | — | — | US | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260104409-A1 | NEXT-GENERATION SEQUENCING FOR PROTEIN MEASUREMENT | SOMALOGIC OPERATING CO INC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-114174245-A | Synthetic method of non-racemic cyclohexene | 巴斯夫公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | BDKRB1 346/4885NPY5R 450/4885MMP2 1079/4885 |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | BDKRB1 346/4885NPY5R 450/4885MMP2 1079/4885 |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | BDKRB1 346/4885NPY5R 450/4885MMP2 1079/4885 |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | BDKRB1 346/4885NPY5R 450/4885MMP2 1079/4885 |
| US-20260104409-A1 | NEXT-GENERATION SEQUENCING FOR PROTEIN MEASUREMENT | PABPC4, MAX, FUS | BDKRB1 3913/4885NPY5R 3569/4885MMP2 3361/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | BDKRB1 275/4885NPY5R 118/4885MMP2 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.